Improved survival time trends for glioblastoma using the SEER 17 population-based registries.

Koshy, Matthew; Villanó, John L.; Dolecek, Therese A.; Howard, Alexander; Chmura, S.J.; Weichselbaum, R.R.; McCarthy, Bridget J.

doi:10.1200/jco.2011.29.15_suppl.2013

Cited by 27 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioblastoma multiforme (GBM) is not only the most common type of brain tumor in adulthood, but also one of the most malignant types of cancer, with a median survival time (World Health Organization grade IV) of 14-15 months with maximum treatment (1). Its infiltrative and heterogeneous characteristics, combined with high proliferation rates, makes treatment challenging.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

et al. 2017

View full text Add to dashboard Cite

Abstract. Despite major contributions to the current molecular understanding of autophagy, a recycling process for intracellular components to maintain homeostatic balance, relatively little is known about the interacting networks. To address this issue, the current study investigated the role of autophagy in primary and established glioblastoma multiforme (GBM) cells and its interplay with the epidermal growth factor receptor (EGFR) and the standard chemotherapeutic agent temozolomide (TMZ). TMZ treatment leads to an upregulation of autophagy, predominantly in primary GBM cells. The interaction between EGFR and Beclin-1, an important protein in initiating autophagy, was assessed using a cancer cell line transfected with EGFR vIII , and by stimulation with EGF. The results of the current study suggest that Beclin-1 and EGFR do not interact directly in either primary or established GBM cells. To enable the limited efficacy of patient treatment strategies of GBM to potentially be enhanced through the application of autophagy regulators, the multiple cellular interactions of autophagy require further elucidation.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Its infiltrative and heterogeneous characteristics, combined with high proliferation rates, makes treatment challenging. Standard therapy includes surgery, adjuvant radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ) (1). TMZ was first identified by Stevens et al in 1984 (2) as an oral anti-cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

et al. 2017

View full text Add to dashboard Cite

show abstract

“…mPFS in this highly selected cohort was 16 months and as a result is being taken forward as a randomized Phase II study [38]. Three population-based studies were presented [42][43][44]. In a Canadian study of 433 patients, only 44% received the SOC (CRT) for newly diagnosed GBM [42].…”

Section: Meeting Reportmentioning

confidence: 99%

“…In a Canadian study of 433 patients, only 44% received the SOC (CRT) for newly diagnosed GBM [42]. An analysis of the Surveillance, Epidemiology and End Results database of 7022 patients revealed an improvement in mOS and 2-year OS over three epochs (2000-2001, 2002-2003 and 2005-2006) suggesting continued improvement in care over time with the introduction of CRT [43]. In an Austrian database, a similar improvement of OS was seen in the contemporary cohort treated with CRT (n = 375) compared with a historical control treated primarily with RT only [44].…”

Section: Meeting Reportmentioning

confidence: 99%

Neuro-oncology: a selected review of ASCO 2011 abstracts

Chamberlain

2011

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

“…Patients with high-grade gliomas experience high morbidity and recurrence with a median survival ranging from just over a year for grade IV tumors [1] and 2–3 years for grade III tumors [2]. Although treatment advances for high-grade gliomas in recent years are promising [3], treatment generally has toxic effects with palliative results.…”

Section: Introductionmentioning

confidence: 99%

Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study

Porter

Menon

Vick

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

Purpose Results from several studies suggest that there is value in evaluating the association between nonclinical characteristics of patients and quality of life (QoL), but few studies have focused on brain cancer. The primary goal of this feasibility study was to explore the relationship between clinical factors and nonclinical factors and QoL in brain cancer patients. Methods Participants in this cross-sectional study were drawn from two hospital sites. Eligible patients were 18–75 years old with a pathologically confirmed diagnosis of a brain cancer histology and stable disease after treatment. Data were obtained from medical chart review and a self-administered survey consisting of main study variables and two QoL standardized measures. Independent sample t test was used to determine differences between patient factors and QoL measures. Results The sample population was comprised of 26 patients with a median age at survey of 57.5 years (range 33–72). Quality of life was adversely associated with younger age, having underage children and living alone. Patients’ meaning of QoL differed by gender, however most patients viewed it as affecting multiple aspects of their lives. Conclusions Nonclinical characteristics were significantly associated with QoL more often than clinical characteristics. Identifying these factors may help improve the quality of care for these patients. This effort demonstrates the relevancy and feasibility of conducting a larger scale study to confirm or refute these findings.

show abstract

Improved survival time trends for glioblastoma using the SEER 17 population-based registries.

Cited by 27 publications

References 22 publications

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

Neuro-oncology: a selected review of ASCO 2011 abstracts

Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study

Contact Info

Product

Resources

About